hi, tj - i have big shares holding right now - will decide if i hold all shares thru the decision and let you know.
share structure here is much better than SG-p

(^_^)/ go! APRI :)

my ST & Twitter ---> @keitrader

APRI mentioned (page 6) ... pdufa 02/17/2018

http://www.rttnews.com/slideshow/3756/biotech-stocks-facing-fda-decision-in-february.aspx?Slide=6

Apricus Biosciences Inc.’s (APRI) resubmitted New Drug Application for Vitaros awaits the FDA's final word, which is expected on February 17, 2018.

Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction, in-licensed from Warner Chilcott Co. Inc., now a subsidiary of Allergan plc. (AGN).

It is approved in Canada, Mexico, and certain countries in Europe, Latin America and the Middle East.

This is Vitaros’ second go-around with the FDA. It was turned down by the U.S. regulatory agency in July 2008, with questions being raised about the results of a transgenic mouse carcinogenicity study, which were completed in 2002.

Will Vitaros make it to the finish line this time?

yes, and its their 2nd try... under the current FDA team, the chance of approval is very high in my personal view :)

XXII - Fighting the tobacco lobby is pretty tough, but the failure of iQOS to prove it is a healthier alternative is a huge gain for VLN. The FDA can't stop smoking. The FDA can limit the amount of nicotine. Big tobacco wants to keep people hooked. The biggest joke is vaping. Why inhale large amounts of nicotine with oily water?

FDA..get the clinical data out and stop beating around the bush. The health benefits are staggering.

this is a super great post, esad! ---> please tweet to him ---> @SGottliebFDA
don't forget to mention XXII ..22nd century group

APRI mentioned. (page 6)

http://www.rttnews.com/slideshow/3756/biotech-stocks-facing-fda-decision-in-february.aspx?Slide=6

Apricus Biosciences Inc.’s (APRI) resubmitted New Drug Application for Vitaros awaits the FDA's final word, which is expected on February 17, 2018.

Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction, in-licensed from Warner Chilcott Co. Inc., now a subsidiary of Allergan plc. (AGN).

It is approved in Canada, Mexico, and certain countries in Europe, Latin America and the Middle East.

This is Vitaros’ second go-around with the FDA. It was turned down by the U.S. regulatory agency in July 2008, with questions being raised about the results of a transgenic mouse carcinogenicity study, which were completed in 2002.

Will Vitaros make it to the finish line this time?

great, its better mention him using XXII & also the company's full name 22nd Century Group

APRI mentioned! (page 6)

http://www.rttnews.com/slideshow/3756/biotech-stocks-facing-fda-decision-in-february.aspx?Slide=6

Apricus Biosciences Inc.’s (APRI) resubmitted New Drug Application for Vitaros awaits the FDA's final word, which is expected on February 17, 2018.

Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction, in-licensed from Warner Chilcott Co. Inc., now a subsidiary of Allergan plc. (AGN).

It is approved in Canada, Mexico, and certain countries in Europe, Latin America and the Middle East.

This is Vitaros’ second go-around with the FDA. It was turned down by the U.S. regulatory agency in July 2008, with questions being raised about the results of a transgenic mouse carcinogenicity study, which were completed in 2002.

Will Vitaros make it to the finish line this time?

APRI closed Thursday’s (Jan.25) trading at $2.32, down 6.16%.

i've heard that the company has enough cash till end of the year, though.

i have a suggestion .. how about we tweet to him saying like ~ look FDA, don't just talk - do something, act fast, move fast and save millions of lives and billions of money... use XXII's technology to reduce man killing nicotine level significantly~ don't just listen to big tobacco makers.

ABIO ~ yap, i tweeted earlier, it made big move since last week.

imo, shorts are trying to cover using small float - its easy to let the pps go down if not many buyers are here and also weak-hands day-traders sell at market order (very bad trades for them) - but how long can they do? - we have big catalysts in a very short time... all in my personal view only.

let's make profit together, Aprilov :)

i'm a good luck charm for APRI

so, the next big news will be P3 data?

i will laugh if we get early FDA approval tomorrow - then, let's count money

This is a low floater..some impatient traders sold at market order.

hit 2.20

what's going on? it hit $2.20

high shorted stock like XXII... placing stops is not a good idea, if you ask me... shorts will take out all those stops.... i put my sell order at way higher than current price (gtc) and no short can borrow my shares.

nice comeback :)

still going down...i wonder why?

i agree suger, APRI will do much much better on FDA approval :)))))

imo, early FDA Approval and buyout :) then, we all should meet in Las Vegas ~ party time!

shorts know what's coming :) btw, SGYP's fda approval is good news for APRI longs :)

nice find :)

congratulations SGYP shareholders!!!
Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

ron, VTGN & CHFS has presentation on 29th at the same place?
please check out CHFS's float.

early approval would be wonderful!~

monday after-hour

but who will write an article?

yes, i see..hope eicoman will write SA article.

we need a nice write up Seeking-Alpha :)

i see.. thank you for your view on SGYP

i agree! APRI

interesting but one year later?

what is the ticker?

OTIC ~ i will take that $9+ :) good luck to us.